Abstract
Dyslipidaemia is common in solid organ transplant recipients and its presence is associated with chronic rejection and accelerated atherosclerosis, leading to an increased prevalence of cardiovascular disease (CVD). CVD is a major cause of morbidity and mortality in transplant recipients. It is therefore of interest and clinical value to introduce agents that effectively and safely reduce the incidence of this outcome. In the present review we consider the potential benefits of statin administration in adults who have undergone solid organ (mainly renal, heart and liver) transplantation, as well as in paediatric transplant patients. We also briefly review the effects of combination therapy with ezetimibe and statins in this population. Overall, statins are efficient and safe drugs for the management of dyslipidaemias in transplant populations, and in most trials they had a beneficial effect on long-term survival rates, CVD events and rejection rates. The transplanted population is different from other patient groups, mostly due to concomitant immunosuppressive therapy. Statins, at an appropriate dosage, should be prescribed to dyslipidaemic transplanted patients but they should be closely monitored for adverse effects.
Keywords: Statins, dyslipidaemia, transplantation, cardiovascular disease, atherosclerosis, rejection
Current Pharmaceutical Design
Title: Statins and Solid Organ Transplantation
Volume: 12 Issue: 36
Author(s): I. F. Gazi, E. N. Liberopoulos, V. G. Athyros, M. Elisaf and D. P. Mikhailidis
Affiliation:
Keywords: Statins, dyslipidaemia, transplantation, cardiovascular disease, atherosclerosis, rejection
Abstract: Dyslipidaemia is common in solid organ transplant recipients and its presence is associated with chronic rejection and accelerated atherosclerosis, leading to an increased prevalence of cardiovascular disease (CVD). CVD is a major cause of morbidity and mortality in transplant recipients. It is therefore of interest and clinical value to introduce agents that effectively and safely reduce the incidence of this outcome. In the present review we consider the potential benefits of statin administration in adults who have undergone solid organ (mainly renal, heart and liver) transplantation, as well as in paediatric transplant patients. We also briefly review the effects of combination therapy with ezetimibe and statins in this population. Overall, statins are efficient and safe drugs for the management of dyslipidaemias in transplant populations, and in most trials they had a beneficial effect on long-term survival rates, CVD events and rejection rates. The transplanted population is different from other patient groups, mostly due to concomitant immunosuppressive therapy. Statins, at an appropriate dosage, should be prescribed to dyslipidaemic transplanted patients but they should be closely monitored for adverse effects.
Export Options
About this article
Cite this article as:
Gazi F. I., Liberopoulos N. E., Athyros G. V., Elisaf M. and Mikhailidis P. D., Statins and Solid Organ Transplantation, Current Pharmaceutical Design 2006; 12 (36) . https://dx.doi.org/10.2174/138161206779026308
DOI https://dx.doi.org/10.2174/138161206779026308 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Medicinal Chemistry of ATP Synthase: A Potential Drug Target of Dietary Polyphenols and Amphibian Antimicrobial Peptides
Current Medicinal Chemistry Neurodegeneration in Niemann-Pick Type C Disease and Huntingtons Disease: Impact of Defects in Membrane Trafficking
Current Drug Targets Effects of Intravenous Apo A-I, HDLs and Apo A-I/Phospholipid Discs on Vascular Metabolism and Atherosclerosis in Animals and Humans
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Hydroxychloroquine (HCQ) Treatment for Hospitalized Patients with COVID- 19
Infectious Disorders - Drug Targets The Therapeutic Role of Xenobiotic Nuclear Receptors Against Metabolic Syndrome
Current Drug Metabolism The Pharmacological Treatment of Cachexia
Current Drug Targets Leber's Hereditary Optic Neuropathy: Novel Views and Persisting Challenges
CNS & Neurological Disorders - Drug Targets Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy
Recent Patents on Anti-Cancer Drug Discovery Evidence of Lifestyle Modification in the Management of Hypercholesterolemia
Current Cardiology Reviews Medical Treatment of COPD Patients with Mild and Moderate Airflow Obstruction
Current Respiratory Medicine Reviews DNA Damage and Epigenetic Changes in Kidney Diseases - Focused on Transcription Factors in Podocytes
Current Hypertension Reviews Treatment of Periodontitis for the Prevention of Endothelial Dysfunction: A Narrative Review
Current Vascular Pharmacology Subject Index to Volume 2
Current Vascular Pharmacology Which way in? The Necessity of Multiple Approaches to Transcatheter Valve Therapy
Current Cardiology Reviews Dynamic Ventricular Repolarisation: From Physiology to Prognosis
Current Cardiology Reviews Platelets and Platelet-Derived Microvesicles as Immune Effectors in Type 2 Diabetes
Current Vascular Pharmacology Current Management of Intermittent Claudication: The Role of Pharmacological and Nonpharmacological Symptom-Directed Therapies
Current Vascular Pharmacology A Comparative Summary on Antioxidant-like Actions of Timolol with Other Antioxidants in Diabetic Cardiomyopathy
Current Drug Delivery Transfusion-related Acute Lung Injury: An Overview
Current Pharmaceutical Design The Anti-Atherogenic Effects of Thiazolidinediones
Current Diabetes Reviews